Clinical

Latest News


Latest Videos


CME Content


More News

5 experts are featured in this series.

Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including gastrointestinal adverse effects and poor absorption, leading many patients to experience iron intolerance or inadequate response, which often necessitates switching to intravenous iron administration for more reliable and rapid repletion of iron stores.

5 experts are featured in this series

Panelists discuss how distinct safety profiles among Bruton tyrosine kinase (BTK) inhibitors—including variations in cardiovascular effects, bleeding risk, infection susceptibility, and other adverse events—guide personalized treatment decisions in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on individual comorbidities and risk factors.

1 expert is featured in this series.

Panelist discusses how rapid access clinics could revolutionize HS patient care by providing swift, comprehensive diagnostic pathways, integrating multidisciplinary expertise, and enabling early intervention. Strategies for equitable access include telemedicine, mobile diagnostic units, community health worker training, sliding-scale pricing, and partnerships with local health care providers to overcome geographical and economic barriers in underserved regions.

5 experts are featured in this series

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy response, BTK C481 mutation status, comorbidities, drug interaction profiles, dosing convenience, and adverse effect considerations, with noncovalent inhibitors offering particular benefit for those with BTK mutations or intolerance to covalent agents.

5 experts are featured in this series.

Panelists discuss how monitoring patients with iron deficiency anemia requires regular follow-up appointments to track laboratory values, assess symptom improvement (particularly fatigue), and evaluate treatment response while considering the impact of comorbid conditions, with adjustments to therapy made based on both objective markers and patient-reported outcomes.

The panelist discusses how recurrent Clostridioides difficile infections represent a critical health care challenge, characterized by unmet needs in long-term prevention, microbiome restoration, and personalized treatment. The field is evolving toward precision medicine approaches, leveraging advanced diagnostics, innovative therapeutic modalities such as engineered probiotics and bacteriophage therapies, and comprehensive strategies that integrate microbial, immunological, and genetic insights to improve patient outcomes.

The panelist discusses how recurrent Clostridioides difficile infections are frequently associated with complex comorbidities including inflammatory conditions, immunocompromise, gastrointestinal disorders, and metabolic diseases. Management requires a nuanced, multidisciplinary approach focusing on tailored antibiotic strategies, immunomodulation, comprehensive diagnostics, and personalized treatment plans.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo